文献速递白血病

费城染色体样B细胞急性淋巴细胞白血病:免疫治疗时代疾病特征与结局

Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
PubMed 文献 · Br J Haematol · 2024-09-18

这项单中心回顾性研究评估了2013年至2024年间治疗的268例成人急性淋巴细胞白血病(ALL)患者(以西班牙裔为主)的结局,其中68例(25.4%)为Ph样、89例(33.2%)为Ph阳性、111例(41.4%)为Ph阴性,并对139例造血干细胞移植(HSCT)患者进行亚组分析。Ph样患者诊断年龄最小(p=0.007)、最易患难治性疾病(p<0.001)、诱导后最不易达到微小残留病(MRD)阴性(p=0.031)。与Ph阴性ALL相比,Ph样ALL的无事件生存期(EFS)更差(HR=1.66;95%CI 1.12-2.46;p=0.012),而Ph阳性ALL的EFS改善(HR=0.60;95%CI 0.38-0.93;p=0.024)且累积复发率(CIR)改善(HR=0.59;95%CI 0.35-0.99;p=0.046)。在移植亚组中,Ph状态不影响无病生存期(DFS)、CIR或总生存期(OS),但HSCT前1年内接受贝林妥欧单抗治疗的患者DFS改善(HR=0.43;95%CI 0.20-0.94;p=0.034)且CIR改善(HR=0.26;95%CI 0.09-0.75;p=0.13)。

要点

  • Ph样ALL患者诊断年龄最小(p=0.007)、最易患难治性疾病(p<0.001)、诱导后最不易达到MRD阴性(p=0.031)。
  • 与Ph阴性ALL相比,Ph样ALL的EFS更差(HR=1.66;95%CI 1.12-2.46;p=0.012)。
  • 移植亚组中,HSCT前1年内接受贝林妥欧单抗治疗者DFS改善(HR=0.43;95%CI 0.20-0.94;p=0.034)。

核心结论

  • 数据提示Ph样ALL对标准诱导治疗应答可能性较低,HSCT可能获得与Ph阴性ALL相似的生存结局。

研究设计与样本

  • 单中心回顾性研究,纳入2013年至2024年间治疗的268例成人ALL患者(以西班牙裔为主),并对139例HSCT患者进行亚组分析。

主要发现

  • ALL亚型包括68例(25.4%)Ph样、89例(33.2%)Ph阳性和111例(41.4%)Ph阴性。
  • Ph样患者诊断年龄最小(p=0.007)、最易患难治性疾病(p<0.001)、诱导后最不易达到MRD阴性(p=0.031)。
  • 与Ph阴性ALL相比,Ph样ALL的EFS更差(HR=1.66;95%CI 1.12-2.46;p=0.012)。
  • 与Ph阴性ALL相比,Ph阳性ALL的EFS改善(HR=0.60;95%CI 0.38-0.93;p=0.024)且CIR改善(HR=0.59;95%CI 0.35-0.99;p=0.046)。
  • 在移植亚组中,Ph状态不影响DFS、CIR或OS;HSCT前1年内接受贝林妥欧单抗治疗的患者DFS改善(HR=0.43;95%CI 0.20-0.94;p=0.034)且CIR改善(HR=0.26;95%CI 0.09-0.75;p=0.13)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Philadelphia chromosome (Ph)-like acute lymphoblastic leukaemia (ALL) is a high-risk subtype with a gene expression profile similar to Ph-positive ALL, due to activation of tyrosine kinase signalling. To understand the clinical implications of Ph-like ALL, this single-centre retrospective study evaluates outcomes in 268 adults, largely Hispanic ALL patients treated between 2013 and 2024, with a subgroup analysis of 139 haematopoietic stem cell transplantation (HSCT) patients. ALL subtypes included 68 (25.4%) Ph-like, 89 (33.2%) Ph-positive, and 111 (41.4%) Ph-negative. Ph-like patients were the youngest age at diagnosis (p = 0.007), most likely to have refractory disease (p < 0.001), and least likely to achieve minimal residual disease (MRD) negativity after induction (p = 0.031). Relative to Ph-negative ALL, Ph-like achieved worse event-free survival (EFS) (HR = 1.66; 95% CI 1.12-2.46; p = 0.012), whereas Ph-positive had improved EFS (HR = 0.60; 95% CI 0.38-0.93; p = 0.024) and cumulative incidence of relapse (CIR) (HR = 0.59; 95% CI 0.35-0.99; p = 0.046). Within the transplant subgroup, Ph status did not impact disease-free survival (DFS), CIR, or overall survival (OS). However, patients who received blinatumomab within 1-year pre-HSCT had improved DFS (HR = 0.43; 95% CI 0.20-0.94; p = 0.034) and CIR (HR = 0.26; 95% CI 0.09-0.75; p = 0.13). In conclusion, our data suggest that Ph-like is less likely to respond to standard induction therapy and HSCT may result in similar survival outcomes to Ph-negative ALL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ashouri K, Hom B, Ginosyan AA, et al. Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy. Br J Haematol. 2024. PMID: 39295195. doi:10.1111/bjh.19771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。